NASDAQ:NBRV - Nabriva Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 885.22 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.20
▲ +0.01 (5.18%)

This chart shows the closing price for NBRV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nabriva Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBRV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBRV

Analyst Price Target is $2.00
▲ +885.22% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Nabriva Therapeutics in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 885.22% upside from the last price of $0.20.

This chart shows the closing price for NBRV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Nabriva Therapeutics. This rating has held steady since March 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/17/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/30/2022Northland SecuritiesLower Price TargetOutperform$4.00 ➝ $2.00High
5/26/2021HC WainwrightReiterated RatingNeutralLow
3/12/2021Northland SecuritiesLower Price TargetOutperform$9.00 ➝ $6.00Medium
9/11/2020HC WainwrightReiterated RatingHoldHigh
8/7/2020HC WainwrightReiterated RatingHoldHigh
6/22/2020Northland SecuritiesLower Price TargetOutperform$2.50 ➝ $1.50High
6/22/2020HC WainwrightReiterated RatingHoldHigh
4/23/2020Northland SecuritiesLower Price TargetOutperform$5.00 ➝ $2.50Low
4/19/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
4/9/2020HC WainwrightDowngradeBuy ➝ Neutral$7.00High
4/8/2020Needham & Company LLCDowngradeBuy ➝ HoldLow
3/19/2020WedbushDowngradeOutperform ➝ Neutral$6.00 ➝ $1.00High
3/17/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$7.00 ➝ $2.00Medium
3/13/2020Needham & Company LLCLower Price TargetBuy$10.00 ➝ $5.00High
3/13/2020HC WainwrightReiterated RatingBuy$7.00High
11/15/2019WedbushReiterated RatingOutperform$7.00High
11/13/2019Needham & Company LLCReiterated RatingBuyHigh
8/20/2019Bank of AmericaSet Price TargetBuy$6.00Medium
8/18/2019HC WainwrightSet Price TargetBuy$7.00High
8/16/2019Northland SecuritiesSet Price TargetBuy$13.00High
8/9/2019WedbushReiterated RatingOutperform$5.00High
8/8/2019Northland SecuritiesReiterated RatingBuy$12.50High
5/9/2019HC WainwrightReiterated RatingBuy$7.00Medium
5/8/2019Northland SecuritiesSet Price TargetBuy$13.00Medium
5/2/2019GabelliUpgradeSell ➝ Hold$2.00Low
5/2/2019HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $7.00Medium
5/1/2019Needham & Company LLCReiterated RatingBuy$15.00 ➝ $10.00High
3/27/2019GabelliDowngradeBuy ➝ Sell$2.56High
3/13/2019HC WainwrightReiterated RatingBuy$9.00High
3/12/2019Northland SecuritiesReiterated RatingBuy$12.50Low
1/28/2019HC WainwrightReiterated RatingBuy$9.00Low
11/14/2018SunTrust BanksLower Price TargetBuy$11.00High
9/7/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$8.00High
8/27/2018Bank of AmericaSet Price TargetBuy ➝ Buy$9.00 ➝ $5.00Medium
8/9/2018Needham & Company LLCSet Price TargetBuy$18.00High
7/25/2018Needham & Company LLCReiterated RatingBuy$18.00High
5/31/2018Northland SecuritiesInitiated CoverageOutperformMedium
5/30/2018Cantor FitzgeraldSet Price TargetBuy$16.00Low
5/22/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$10.00 ➝ $11.00High
5/21/2018Cantor FitzgeraldSet Price TargetBuy$16.00High
5/8/2018Needham & Company LLCReiterated RatingBuy$18.00Medium
5/8/2018Cantor FitzgeraldSet Price TargetBuy$16.00Medium
3/21/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$10.00High
3/19/2018WedbushReiterated RatingOutperformHigh
3/16/2018Cantor FitzgeraldSet Price TargetBuy$16.00Low
1/17/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$10.00High
11/16/2017HC WainwrightReiterated RatingBuy$20.00N/A
11/1/2017HC WainwrightBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.00N/A
9/19/2017Needham & Company LLCReiterated RatingBuy$15.00 ➝ $18.00High
9/19/2017HC WainwrightReiterated RatingBuy$18.00High
9/18/2017WedbushReiterated RatingOutperform$13.00 ➝ $21.00Medium
9/18/2017SVB LeerinkReiterated RatingOutperform$20.00 ➝ $22.00Medium
9/18/2017SunTrust BanksBoost Price TargetBuy$20.00 ➝ $24.00High
9/18/2017Cantor FitzgeraldReiterated RatingBuy$16.00High
9/1/2017Cantor FitzgeraldReiterated RatingBuy$16.00High
8/28/2017HC WainwrightReiterated RatingBuy$16.00 ➝ $18.00Low
8/25/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$20.00Medium
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/18/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/19/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/18/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/18/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2022
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/16/2022

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Nabriva Therapeutics logo
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $0.20
Low: $0.19
High: $0.21

50 Day Range

MA: $0.19
Low: $0.17
High: $0.22

52 Week Range

Now: $0.20
Low: $0.16
High: $1.40

Volume

2,143,298 shs

Average Volume

1,073,498 shs

Market Capitalization

$135.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Nabriva Therapeutics?

The following Wall Street sell-side analysts have issued reports on Nabriva Therapeutics in the last year: Northland Securities, and StockNews.com.
View the latest analyst ratings for NBRV.

What is the current price target for Nabriva Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Nabriva Therapeutics in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 885.2%. Northland Securities has the highest price target set, predicting NBRV will reach $2.00 in the next twelve months. Northland Securities has the lowest price target set, forecasting a price of $2.00 for Nabriva Therapeutics in the next year.
View the latest price targets for NBRV.

What is the current consensus analyst rating for Nabriva Therapeutics?

Nabriva Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NBRV will outperform the market and that investors should add to their positions of Nabriva Therapeutics.
View the latest ratings for NBRV.

What other companies compete with Nabriva Therapeutics?

How do I contact Nabriva Therapeutics' investor relations team?

Nabriva Therapeutics' physical mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The biotechnology company's listed phone number is (531) 649-2000 and its investor relations email address is [email protected] The official website for Nabriva Therapeutics is www.nabriva.com. Learn More about contacing Nabriva Therapeutics investor relations.